Rheumatoid arthritis (RA) is an autoimmune disease that causes the body’s immune system to attack joint tissues, which leads to inflammation of joint lining. Such inflammation of joint lining causes pain, stiffness, swelling, warmth, and redness. Rheumatoid arthritis is most prevalent among women. RA can be diagnosed through two methods, namely X–ray imaging and blood tests/serology test. This report tracks revenue generated through sales of test kits used to diagnose the presence of rheumatoid arthritis. However, the report excludes revenue generated through sales of analyzers that are used during RA diagnosis procedures. Sample processing methods such as duplicate/triplicate sample run have been excluded from the scope of the study.
This report covers global rheumatoid arthritis market performance in terms of value and volume contribution. The report includes key trends, drivers, restraints, and opportunities influencing the growth of the global rheumatoid arthritis market over the forecast period (2016-2022). Impact analysis of key growth drivers and restraints based on the weighted average model are included in this report to better equip clients with crystal clear decision-making insights. Various types of kits used to ascertain the amount of substance in samples across hospitals, diagnostic laboratories, ambulatory surgical centers have been considered in this report.
Increasing spending on drug development for arthritis and other musculoskeletal diseases and financial support by government authorities to monitor rheumatoid arthritis prevalence are prime factors driving the growth of rheumatoid arthritis tests market. Moreover, increasing the prevalence of autoimmune diseases and unavailability of medication are boosting the growth of the RA treatment efficiency monitoring tests market. However, high-cost novel test kits, limited sensitivity and specificity and strong retaliation from local manufacturers regarding sales of these kits are some of the prominent factors impeding the growth of rheumatoid arthritis tests market.
Global rheumatoid arthritis diagnosis tests market has been estimated to be valued at US$ 485.5 Mn in 2015, and is anticipated to increase to US$ 738.7 Mn by 2022, registering a CAGR of 6.2% during the forecast period.
By test type, the global rheumatoid arthritis diagnosis tests market is segmented into serology test and RA treatment efficiency monitoring tests. Serology test segment is further sub-segmented into erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), antinuclear antibody (ANA), uric acid test, other tests. RA treatment efficiency monitoring tests segment is further sub-segmented into Salicylate Level Count, Muscle Enzyme Tests (CPK, Aldolase) and Creatinine Test.
By end user, the global rheumatoid arthritis diagnosis tests market is segmented into hospitals, diagnostic laboratories, and ambulatory surgical centers. Diagnostic laboratory segment is further sub-segmented into private laboratories and public laboratories.
By region, the Europe and Asia Pacific regions have been estimated to remain dominant with over 61% share of the global market by 2022. This is mainly due to increase prevalence of autoimmune diseases and higher adoption of novel RA diagnostic kits. North America market is estimated to lose 60 BPS over the forecast period, owing to a slight decrease in the prevalence rate of rheumatoid arthritis.
Global rheumatoid arthritis market is segmented as follows:
By Test Type
By End Users
Key features of this report
MRRSE offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.Get A Free Custom Research Quote